– USA, IN – Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced the appointment of Sue Mahony, PhD, to its board of directors, increasing the number of directors from seven to eight. Dr. Mahony will also serve as a member of the Science and Technology Committee.

“Dr. Mahony brings Assembly expertise from a distinguished pharmaceutical industry career spanning multiple disciplines and geographic territories,” said William Ringo, Assembly’s chairman of the board. “Her broad business perspective and varied operational experience should be especially valuable as we advance our innovative antiviral and microbiome products in global clinical development.”

During a 28-year career, Dr. Mahony has served in diverse leadership roles in sales, marketing, clinical development, human resources and general management. She held positions at Amgen, Schering-Plough, Bristol-Myers Squibb and Lilly, with global and direct responsibility for operations in the US, Japan, China, Europe and Canada. In 2009, Dr. Mahony was appointed senior vice president, human resources and diversity at Eli Lilly and Company. Prior to that, she led Lilly’s operations in Canada. Dr. Mahony currently serves as president, Lilly Oncology, a senior vice president at Eli Lilly and Company, and a member of the company’s Executive Committee.

Dr. Mahony earned both Bachelor of Science and PhD degrees in pharmacy from Aston University in the UK, which also awarded her an honorary doctorate degree. She received an MBA from the London School of Business and in 2010, she was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Dr. Mahony is a member of the Board of Directors of the Park Tudor School in Indianapolis.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company’s microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications.

For more information : http://www.assemblybio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.